ORDENTLICH PETER (Chief Scientific Officer) sold 69.00 shares of SYNDAX PHARMACEUTICALS INC on the open market
Open‑market sale worth $2.0K. Review remaining holdings and any 10b5‑1 plan disclosures.
S · 1 sale
Filed: 2/3/2023ACC: 0001562180-23-000950
Officer· Chief Scientific Officer
Since Feb 2019
+90K
Net shares
Net buyer
$2.0K
Total sold
1
Open market trades
0B · 1S
3
Total transactions
90.07K acquired · 69.00 disposed
Non-Derivative Transactions2
Common Stock
Direct
Shares
+69.00
Price / share
$17.32
Trade value
$1.20K
% of position
New position
1/31/2023
0.00→69.00
Common Stock
Direct
Shares
−69.00
Price / share
$28.43
Trade value
$1.96K
% of position
New position
2/1/2023
69.00→0.00
Total
Net shares
+0.00
Net value
-$766.46
| Security | Date | Type | Shares | Price / Share | Trade Value | % of Position | Held Before | Held After |
|---|---|---|---|---|---|---|---|---|
| Common Stock Direct | 1/31/2023 | J · J | +69.00 | $17.32 | $1.20K | New position | 0.00 | 69.00 |
| Common Stock Direct | 2/1/2023 | S · Sale | −69.00 | $28.43 | $1.96K | New position | 69.00 | 0.00 |
| Total | +0.00 | -$766.46 | ||||||
Derivative Transactions1
Stock Options (Right to buy)
Direct
Converts to
Common Stock
90K shares
Shares
+90K
Strike price
28.55
Held after
90K
Exercisable
—
2/2/2023
| Security | Converts To | Date | Type | Shares | Strike Price | Exercisable | Held After |
|---|---|---|---|---|---|---|---|
| Stock Options (Right to buy) Direct | Common Stock90K shares | 2/2/2023 | A · Award | +90K | 28.55 | — | 90K |